Though artificial bioactive compounds are permitted in lots of nations for meals functions, they’re changing into much less and fewer welcome by customers. Due to this fact, there was an growing curiosity in changing these artificial compounds by pure bioactive compounds. These pure compounds can be utilized as meals components to take care of the meals high quality, meals security and attraction, and as meals dietary supplements or nutraceuticals to right dietary deficiencies, keep an appropriate consumption of vitamins, or to assist physiological capabilities, respectively.
Latest research reveal that quite a few meals wastes, significantly fruit and greens byproducts, are a very good supply of bioactive compounds that may be extracted and reintroduced into the meals chain as pure meals components or in meals matrices for acquiring nutraceuticals and purposeful meals. This evaluation addresses common questions regarding using fruit and greens byproducts as new sources of pure bioactive compounds which can be being addressed to meals as pure components and dietary supplements. These bioactive compounds should observe the authorized necessities and evaluations to evaluate the dangers for human well being and their toxicity should be thought-about earlier than being launched into the market.
To beat the potential well being danger whereas growing the organic exercise, stability and biodistribution of the dietary supplements’ technological options have been studied comparable to encapsulation of bioactive compounds into micro or nanoparticles or nanoemulsions. It will permit enhancing the soundness and launch alongside the gastrointestinal tract in a managed method into the precise tissues. This evaluation summarizes the valorization path {that a} bioactive compound recovered from an agro-food waste can face from the second their potentialities are exhibited till it reaches the ultimate client and the protection and toxicity challenges, they could overcome.
Preclinical Bioavailability, Tissue Distribution, and Protein Binding Research of Erinacine A, a Bioactive Compound from Hericium erinaceus Mycelia Utilizing Validated LC-MS/MS Methodology
Erinacine A, derived from the mycelia of Hericium erinaceus, has attracted a lot consideration because of its neuroprotective properties. Nevertheless, only a few research have been carried out on the bioavailability, tissue distribution, and protein binding of erinacine A. This research aimed to analyze the bioavailability, tissue distribution, and protein binding of erinacine A in Sprague-Dawley rats. After oral administration (po) and intravenous administration (iv) of two.381 g/kg BW of the H. erinaceus mycelia extract (equal to 50 mg/kg BW of erinacine A) and 5 mg/kg BW of erinacine A, respectively, absolutely the bioavailability of erinacine A was estimated as 24.39%.
Erinacine A was detected in mind at 1 h after oral dosing and reached the height at eight h. Protein binding assay confirmed unbound erinacine A fractions in mind to blood ratio is near unity, supporting passive diffusion because the dominating transport. Feces was the foremost route for the elimination of erinacine A. This research is the primary to indicate that erinacine A can penetrate the blood-brain barrier of rats by the technique of passive diffusion and thus assist the event of H. erinaceus mycelia for the development of neurohealth.
Enzymatic pretreatment of seeds is a novel method that enhances the well being advantages of the extracted oil. The research investigated the affect of the enzymatic pretreatment of seeds on the standard of oil from totally different pomegranate cultivars. The standard of the ultrasound-assisted (and ethanol-extracted) oil was studied, with respect to the refractive index (RI), yellowness index (YI), conjugated dienes (Ok232), peroxide worth (PV) ρ-anisidine worth (AV), whole oxidation worth (TOTOX), whole carotenoid content material (TCC), whole phenolic compounds (TPC), fatty acid composition, phytosterol composition, ferric lowering antioxidant energy (FRAP), and a pair of.2-diphenyl-1-picryl hydrazyl (DPPH) radical scavenging capability.
Dedication of Bioactive Compounds in Sequential Extracts of Chia Leaf ( Salvia hispanica L.) Utilizing UHPLC-HRMS (Q-Orbitrap) and a World Analysis of Antioxidant In Vitro Capability
Shoppers’ curiosity in meals which can be nutritionally balanced and with well being advantages has elevated. The meals trade is being attentive to using the ancestral seed Salvia hispanica L., generally often known as chia. At current, solely chia seeds, that are a pure supply of omega-Three and omega-6, fiber, proteins, and pure antioxidants, are commercialized. Though some research reveal the presence of a number of bioactive compounds, comparable to polyphenols (e.g., vitexin, orientin, and a few hydroxycinnamic acids) in chia leaf methanolic extracts, the chia plant is usually used as fertilizer or handled as waste after harvest.
Due to this fact, it might symbolize a by-product that may very well be thought-about an incredible supply of bioactive compounds with unexplored potential in medication and meals trade functions. On this work, UHPLC-HRMS (Q-Orbitrap) was employed to tentatively determine and decide the bioactive compounds current in numerous leaf extracts of chia crops of black and white seed phenotype obtained with solvents of various polarity (ethanol, ethyl acetate, dichloromethane, and hexane) to handle chia plant by-product revalorization. The chemical antioxidant capability was additionally studied and correlated to the discovered bioactive compounds.
C8orf55 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K0261504 | ABM | 1.0 ug DNA | EUR 154 |
C8orf55 3'UTR Luciferase Stable Cell Line |
|||
TU002535 | ABM | 1.0 ml | EUR 1394 |
C8orf55 3'UTR GFP Stable Cell Line |
|||
TU052535 | ABM | 1.0 ml | EUR 1394 |
C8orf55 Protein Vector (Human) (pPB-C-His) |
|||
PV066905 | ABM | 500 ng | EUR 552 |
C8orf55 Protein Vector (Human) (pPB-N-His) |
|||
PV066906 | ABM | 500 ng | EUR 552 |
C8orf55 Protein Vector (Human) (pPM-C-HA) |
|||
PV066907 | ABM | 500 ng | EUR 552 |
C8orf55 Protein Vector (Human) (pPM-C-His) |
|||
PV066908 | ABM | 500 ng | EUR 552 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K0261505 | ABM | 3 x 1.0 ug | EUR 376 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
K0261506 | ABM | 1.0 ug DNA | EUR 167 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
K0261507 | ABM | 1.0 ug DNA | EUR 167 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
K0261508 | ABM | 1.0 ug DNA | EUR 167 |
H2B Antibody Antibody |
|||
AF4659 | Affbiotech | 200ul | EUR 376 |
Description: H2B Antibody Antibody detects endogenous levels of H2B. |
CD11b Antibody Antibody |
|||
ABD2911 | Lifescience Market | 100 ug | EUR 438 |
anti- Antibody^Polyclonal antibody control antibody |
|||
LSMab09882 | Lifescience Market | 100 ug | EUR 438 |
Antibody |
|||
A1360-500 | Biovision | Ask for price |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx123734 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
abx036399-100ug | Abbexa | 100 ug | EUR 391 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx008109 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx033330-400ul | Abbexa | 400 ul | EUR 523 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx033330-80l | Abbexa | 80 µl | EUR 286 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319913 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx311665 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
abx230204-100ug | Abbexa | 100 ug | EUR 481 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx234901-100ug | Abbexa | 100 ug | EUR 551 |
Anti-Anti-SEPT6 antibody antibody |
|||
STJ11100949 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
|||
STJ111369 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ111530 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT4 Antibody antibody |
|||
STJ112276 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-MARCH9 Antibody antibody |
|||
STJ112609 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ25475 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ25477 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ25479 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ28365 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ28963 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx324434 | Abbexa |
|
|
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ116214 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ117206 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT12 Antibody antibody |
|||
STJ117759 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118549 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118550 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-MARCH7 Antibody antibody |
|||
STJ118752 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT3 Antibody antibody |
|||
STJ118990 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT1 antibody antibody |
|||
STJ119580 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ113941 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ114081 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ114819 | St John's Laboratory | 100 µl | EUR 277 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-MARCH8 Antibody antibody |
|||
STJ114828 | St John's Laboratory | 100 µl | EUR 277 |
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
abx023924-1mg | Abbexa | 1 mg | EUR 1205 |
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
|||
abx411057-50ug | Abbexa | 50 ug | EUR 592 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319929 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319930 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319931 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
|||
20-abx311666 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
|||
20-abx311667 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
|||
20-abx311668 | Abbexa |
|
|
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
|||
abx233571-100ug | Abbexa | 100 ug | EUR 481 |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D | Stressmarq | 0.1mg | EUR 354 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A390 | Stressmarq | 0.1mg | EUR 401 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A488 | Stressmarq | 0.1mg | EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A565 | Stressmarq | 0.1mg | EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A594 | Stressmarq | 0.1mg | EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A633 | Stressmarq | 0.1mg | EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A655 | Stressmarq | 0.1mg | EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A680 | Stressmarq | 0.1mg | EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A700 | Stressmarq | 0.1mg | EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-ALP | Stressmarq | 0.1mg | EUR 394 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-APC | Stressmarq | 0.1mg | EUR 399 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-APCCY7 | Stressmarq | 0.1mg | EUR 471 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-BI | Stressmarq | 0.1mg | EUR 396 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY350 | Stressmarq | 0.1mg | EUR 414 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY405 | Stressmarq | 0.1mg | EUR 403 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY488 | Stressmarq | 0.1mg | EUR 393 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY594 | Stressmarq | 0.1mg | EUR 395 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY633 | Stressmarq | 0.1mg | EUR 390 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-FITC | Stressmarq | 0.1mg | EUR 392 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
In these experiments, black chia confirmed the next antioxidant capability than white chia within the ethanolic extracts. Furthermore, experiments on mobile antioxidant exercise have been additionally carried out with a predominance of the white chia extract. It’s famous that the mobile antioxidant exercise outcomes make chia ethanolic extracts promising antioxidants.